Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Colorcon
Baxter
McKesson

Last Updated: September 26, 2022

Details for Patent: 8,545,402


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 8,545,402
Title:Highly reliable ingestible event markers and methods for using the same
Abstract: Ingestible event markers having high reliability are provided. Aspects of the ingestible event markers include a support, a control circuit, a first electrochemical material, a second electrochemical material and a membrane. In addition, the ingestible event markers may include one or more components that impart high reliability to the ingestible event marker. Further, the ingestible event markers may include an active agent. In some aspects, the active agent, such as a pharmaceutically active agent or a diagnostic agent may be associated with the membrane.
Inventor(s): Hafezi; Hooman (Redwood City, CA), Au-Yeung; Kityee (San Francisco, CA), Duck; Robert (San Francisco, CA), Holen; Maria (Santa Clara, CA), Robertson; Timothy (Belmont, CA), Costello; Benedict (Berkeley, CA)
Assignee: Proteus Digital Health, Inc. (Redwood City, CA)
Application Number:12/744,642
Patent Claim Types:
see list of patent claims
Dosage form;

Drugs Protected by US Patent 8,545,402

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-001 Nov 13, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-002 Nov 13, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-003 Nov 13, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-004 Nov 13, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-005 Nov 13, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-006 Nov 13, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,545,402

PCT Information
PCT FiledApril 27, 2010PCT Application Number:PCT/US2010/032590
PCT Publication Date:November 11, 2010PCT Publication Number: WO2010/129288

International Family Members for US Patent 8,545,402

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 122013009559 See Plans and Pricing
Brazil PI1015298 See Plans and Pricing
Chile 2011002700 See Plans and Pricing
China 102458236 See Plans and Pricing
Costa Rica 20110624 See Plans and Pricing
Eurasian Patent Organization 201190281 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
AstraZeneca
Mallinckrodt
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.